-
Brean Downgrades Revance Therapeutics Following RT-001 Fail
Tuesday, June 14, 2016 - 8:53am | 139Read More...Brean Capital's Difei Yang downgraded Revance Therapeutics Inc (NASDAQ: RVNC) from Buy to Hold and removed the price target. The downgrade came after RT-001 failed a Phase III study for Crow's Feet. Related Link: Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out Besides RT-...
-
Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out
Tuesday, May 24, 2016 - 10:11am | 338Read More...Brean Capital has reiterated its Buy rating on Revance Therapeutics Inc (NASDAQ: RVNC) ahead of the upcoming Phase III read-out of RT001 (lateral canthal lines), which is expected in the next 1.5 months. RT001 is currently in a late-stage study in the United States for the treatment of lateral...
-
Brean Thinks Relypsa's Veltassa Sales Were 'Solid, But Not Impressive'
Tuesday, May 17, 2016 - 8:46am | 274Read More...Relypsa Inc (NASDAQ: RLYP) disclosed Veltassa prescription data for April in its 8-K on May 16. Brean Capital’s Difei Yang reiterated a Buy rating on the company, with a price target of $26. April Prescription Data “The numbers, including retail and non-retail TRx, were solid, though...
-
Brean's Yang: Relypsa Monthly Prescription Data Met Expectations, A Takeout Still 'Probable'
Friday, April 15, 2016 - 12:36pm | 281Read More...Relypsa Inc (NASDAQ: RLYP)’s March prescription data was in line with analyst expectations, but the stock is selling off hard in Friday’s session. Despite the 14.5 percent sell-off, Brean Capital analyst Difei Yang believes the stock still has plenty of upside. “While the data...
-
Brean Initiates Relypsa With Buy Rating, $26 Target
Tuesday, March 29, 2016 - 9:32am | 291Read More...On Tuesday, Brean Capital issued a company note on Relypsa Inc (NASDAQ: RLYP), initiating coverage on the biopharmaceutical company after recent analysis of their drug Veltassa, which treats hyperkalemia. Currently, analysts at Brean Capital rate Relypsa as a Buy with a $26 price target. Difei...
-
Brean: Pernix Deal Could Occur Soon, Stock Worth $8
Tuesday, February 9, 2016 - 10:14am | 309Read More...Pernix Therapeutics Holdings Inc (NASDAQ: PTX) shares have dipped 74.85 percent over the past one year, almost down to their 52-week low on February 5, at $1.99. Brean Capital’s Difei Yang has maintained a Buy rating on the company, while lowering the price target from $14 to $8. On...
-
Brean Reiterates Buy On Horizon Pharma, Likes Crealta Deal
Monday, December 14, 2015 - 11:40am | 343Read More...On Monday, Brean Capital issued a company update on Horizon Pharma PLC (NASDAQ: HZNP) after the pharmaceutical company announced the acquisition of Crealta Holdings LLC. Currently, Brean rates Horizon as a Buy and raised their price target from $31 to $32. Difei Yang, an analyst at Brean Capital,...
-
Premium No Longer Deserved? Why Brean's Difei Yang Is Downgrading Horizon Pharma
Tuesday, September 22, 2015 - 9:16am | 345Read More...Although Horizon Pharma PLC (NASDAQ: HZNP) shares have declined since September 21, they are up 128 percent since September 15. Brean's Difei Yang downgraded the rating on the company from Buy to Hold, while removing the price target. Recent negative developments for the sector as...
-
Brean Capital Initiates Coverage On Osiris Therapeutics
Monday, December 29, 2014 - 6:05pm | 291Read More...Brean Capital initiated coverage on Osiris Therapeutics, Inc. (NASDAQ: OSIR) Monday with a Buy rating and $19 price target. Analyst Difei Yang liked “the company for bringing the pharmaceutical quality of clinical research to the wound care space and as it also appears that Osiris has...
-
Brean Capital Initiates Coverage On Zogenix
Monday, December 29, 2014 - 5:44pm | 222Read More...Brean Capital initiated coverage on Zogenix, Inc. (NASDAQ: ZGNX) Monday with a Buy rating and $2.50 price target. Analyst Difei Yang commented that “Zogenix has commercialized a controversial product, Zohydro ER, and we believe the market under-appreciates the medical value this product...
-
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix
Tuesday, August 5, 2014 - 2:24pm | 159Read More...Zohydro in March was blocked by regulators in the state of Massachusetts. On Monday, however, Zohydro was included back onto the MassHealth drug list, with “prior authorization." According to Masshealth, "The updates to the List are effective immediately, unless otherwise...
-
Could ViroPharma Benefit from Multiple Generic Versions of VANCOCIN?
Wednesday, April 11, 2012 - 12:28pm | 374Read More...Yesterday morning, the US Food and Drug Administration approved three drug manufacturers' generic versions of ViroPharma's (NASDAQ: VPHM) VANCOCIN HCl capsules. According to Watson Pharmaceuticals' (NYSE: WPI) statment, VANCOCIN is indicated for the treatment of C. difficile-associated diarrhea and...
